Phathom Pharmaceuticals Q1 Revenue More Than Doubles, Beats Estimates on Strong VOQUEZNA Sales
PHAT has more than doubled off its 52-week low of $2.21 on elevated volume (2.7× avg).
Summary
Phathom Pharmaceuticals reported robust first-quarter results, with revenue more than doubling to $58.30 million, surpassing analyst estimates of $57.03 million. The company also beat adjusted EPS expectations, reporting -$0.18 against a consensus of -$0.32. This strong performance was primarily driven by a 115% year-over-year increase in VOQUEZNA prescriptions and a 40% reduction in operating expenses. The results reinforce the company's positive trajectory, aligning with its previous 10-K projection of achieving operating profitability by Q3 2026 and maintaining its 2026 net revenue guidance of $320-$345 million. This significant operational improvement and strong product growth are material positives for the stock, indicating effective execution of its commercial strategy. Traders will now focus on the company's progress towards its Q3 profitability target and sustained VOQUEZNA growth.
At the time of this announcement, PHAT was trading at $12.30 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $935.7M. The 52-week trading range was $2.21 to $18.31. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Reuters.